Eli Lilly says its experimental diabetes therapy basal insulin peglispro beat out Sanofi’s blockbuster Lantus for reducing levels of HbA1c in a trio of late-stage trials. But at least one prominent analyst swiftly raised questions about potential safety issues for this Lantus rival, which hopes to bite off a big piece of the market as Sanofi settles in for a lengthy legal battle to protect one of its bestselling products.

…read more

Source: Lilly draws flak after touting PhIII diabetes success for Lantus rival


0 No comments